Pfizer’s BRAFTOVI® combination regimen has demonstrated a 51% reduction in the risk of death and a 47% decrease in disease progression for patients with BRAF V600E-mutant metastatic colorectal cancer, according to the pivotal Phase 3 BREAKWATER trial.
Sanofi’s real-world study shows that infant immunization with BEYFORTUS® offers stronger protection against RSV-related hospitalizations compared to maternal immunization strategies.
Johnson & Johnson MedTech’s MONARCH™ Platform demonstrated 98.7% navigation success and 83.2% diagnostic yield in the TARGET study, confirming its safety and efficacy for robotically assisted bronchoscopy.
GSK has halted its Phase III PIVOT-PO trial early after an independent review confirmed tebipenem HBr met its primary efficacy goal in treating complicated urinary tract infections, marking a major step forward for oral antibiotic options.
Abbott’s Tendyne™ device has secured FDA approval, revolutionizing mitral valve replacement. This minimally invasive system offers a crucial alternative for high-risk patients with severe mitral annular calcification, eliminating the need for open-heart surgery.
Trastuzumab is a monoclonal antibody that has been engineered to attack and block the human epidermal growth factor receptor 2 (HER2), a protein that contributes to cancer cell growth. It is used most frequently to treat HER2-positive breast cancer and HER2-positive gastric cancer. As [Read More…]
GSK’s Blenrep combinations have received a positive opinion from the CHMP for treating relapsed/refractory multiple myeloma, backed by strong Phase III trial results showing improved survival outcomes.
XTANDI® (enzalutamide), co-developed by Astellas and Pfizer, has shown a significant 30% reduction in risk of death over five years in metastatic hormone-sensitive prostate cancer (mHSPC) patients, marking it as the first androgen receptor inhibitor to demonstrate this long-term survival benefit.
Roche’s Susvimo® has received FDA approval for diabetic retinopathy, becoming the first continuous delivery treatment offering sustained vision benefits with just one refill every nine months. Backed by strong Phase III results, the implant provides a long-term solution for millions at risk of vision loss.
Potentially Groundbreaking Treatment Could Delay or Prevent Progression to Full-Blown Myeloma.
